Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 17Recruiting 8Active not recruiting 8Withdrawn 2Unknown 2Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Non-Small-Cell Lung 79Nasopharyngeal Carcinoma 51Uterine Cervical Neoplasms 44Lung Neoplasms 38Esophageal Neoplasms 32Head and Neck Neoplasms 28Esophageal Squamous Cell Carcinoma 28Squamous Cell Carcinoma of Head and Neck 22Stomach Neoplasms 20Breast Neoplasms 16Small Cell Lung Carcinoma 15Recurrence 12Neoplasm Metastasis 12Nasopharyngeal Neoplasms 12Carcinoma, Squamous Cell 10Ovarian Neoplasms 9Central Nervous System Neoplasms 9Neuroblastoma 8Lymphoma, Large B-Cell, Diffuse 8Pancreatic Neoplasms 7Lymphoma 7Hypopharyngeal Neoplasms 7Triple Negative Breast Neoplasms 6Oropharyngeal Neoplasms 6Neoplasms 6Biliary Tract Neoplasms 6Urinary Bladder Neoplasms 5Lymphoma, Non-Hodgkin 5Lymphoma, Large-Cell, Immunoblastic 5Lymphoma, Follicular 5

Interventions

toripalimab 4pembrolizumab 4Gemcitabine 4tislelizumab 2durvalumab 2Nivolumab 2Cisplatin 2Carboplatin 2AZD4547 2tipifarnib 1tesetaxel 1sapanisertib 1regorafenib 1pyrotinib 1nintedanib 1famitinib 1disitamab vedotin 1camrelizumab 1bintrafusp alfa protein, human 1atezolizumab 1anlotinib 1aldesleukin 1advexin 1Vitamin B 12 1Trastuzumab 1Taxes 1Surgical Procedures, Operative 1Saline Solution 1Resistance Training 1Pemetrexed 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Carcinoma, Transitional Cell × Cisplatin × Clear all
NCT05030077 2021-09-01

Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma

Tianjin Medical University Second Hospital

Phase 2 Unknown
53 enrolled
Genitourinary

Carcinoma, Transitional Cell, Urogenital Neoplasms

NCT04568304 2020-09-29

A Study Evaluating Toripalimab Injection Combined With Standard Chemotherapy as a First-line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma

Shanghai Junshi Bioscience Co., Ltd.

Phase 3 Unknown
364 enrolled
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡